Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Name: Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
Published: 2019
License: Public Domain

National Cancer Institute (NCI) · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

fallopian tube endometrioid tumor, fallopian tube high grade serous adenocarcinoma, malignant ovarian endometrioid tumor, ovarian high grade serous adenocarcinoma, platinum-sensitive fallopian tube carcinoma, platinum-sensitive ovarian carcinoma, platinum-sensitive primary peritoneal carcinoma, primary peritoneal high grade serous adenocarcinoma, recurrent fallopian tube carcinoma, recurrent fallopian tube endometrioid adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian serous adenocarcinoma

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 827648
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.